Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/NOVARTIS-AG-9364983/news/Novartis-New-data-reinforces-clinical-basis-for-switching-to-Sandoz-biosimilar-medicines-25499794/?utm_source=whatsapp&utm_medium=social&utm_campaign=share